The challenge study, in which 84 adults completed the challenge after receiving two doses of the vaccine or placebo, showed that the vaccine was generally well tolerated, and demonstrated 47% efficacy against any norovirus illness, including mild illness, and 26% efficacy against norovirus infection.
LigoCyte Pharma CEO Donald Beeman said that they were pleased with the opportunity to share the important results from this carefully designed proof-of-concept, multi-center challenge study.
"The study data are very encouraging, indicating reductions in clinical norovirus illness, infection, and severity of illness in subjects who received vaccine compared to those who received placebo," Beeman said.